Please assess the completion status of the following clinical trial:

Trial Title: Rifaximin for Functional Dyspepsia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Non-ulcer dyspeptic patients who fulfill post-prandial distress syndrome according to the Rome III Criteria~* Active dyspeptic symptom~* Normal upper endoscopy~* Urea Breath Test -ve or Rapid urease test -ve~* Not typical gastroesophageal reflux or biliary colic symptoms, but presence of infrequent acid reflux is allowed~Exclusion Criteria:~* No active dyspeptic symptom~* Allergic to rifaximin~* Recent antibiotics use in the past 8 wk~* Recent PPI or H2RA in past 4 wk~* On anti-coagulants, anti-convulsant or oral contraceptives~* On NSAIDs, aspirin or Clopidogrel~* Pregnancy or breast feeding~* Previous gastric surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Rifaximin (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).